Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells

Journal of Immunology

Volumn 178, Issue 1, 2007, Pages 613-622

  Koido, Shigeo ^a,c   Hara, Eiichi ^b   Homma, Sadamu ^a   Torii, Akira ^a   Mitsunaga, Makoto ^a   Yanagisawa, Satoru ^a   Toyama, Yoichi ^a   Kawahara, Hidejiro ^a   Watanabe, Michiaki ^a   Yoshida, Seiya ^a   Kobayashi, Susumu ^a   Yanaga, Katsuhiko ^a   Fujise, Kiyotaka ^a   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c Jikei University School of Medicine ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MUCIN 1; PICIBANIL;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUSION; CELL MATURATION; CELL STIMULATION; COLORECTAL CANCER; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33845927976     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.1.613     Document Type: Article

References (50)

1. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9: 271-296.
2. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
3. Cella, M., F. Sallusto, and A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9: 10-16.
4. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
5. Koido, S., M. Kashiwaba, D. Chen, S. Gendler, D. Kufe, and J. Gong. 2000. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165: 5713-5719.
6. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183: 317-322.
7. Russo, V., S. Tanzarella, P. Dalerba, D. Rigatti, P. Rovere, A. Villa, C. Bordignon, and C. Traversari. 2000. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl. Acad. Sci. USA 97: 2185-2190.
8. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561.
9. Gong, J., D. Chen, M. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Qu, G. J. Rowse, S. J. Gendler, and D. Kufe. 1998. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95: 6279-6283.
10. Gong, J., N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165: 1705-1711.
11. Koido, S., Y. Tanaka, D. Chen, D. Kufe, and J. Gong. 2002. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1- transgenic mice. J. Immunol. 168: 2111-2117.
12. Koido, S., E. Hara, A. Torii, S. Homma, Y. Toyama, H. Kawahara, M. Ogawa, M. Watanabe, K. Yanaga, K. Fujise, J. Gong, and G. Toda. 2005. Induction of antigen-specific CD4 and CD8 mediated T cell responses by fusion of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer 117: 587-595.
13. Gong, J., S. Koido, Y. Kato, Y. Tanaka, D. Chen, A. Jonas, I. Galinsky, D. DeAngelo, D. Avigan, D. Kufe, and R. Stone. 2004. Induction of antileukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 28: 1303-1312.
14. Koido, S., M. Ohana, C. Liu, N. Nikrui, J. Durfee, A. Lerner, and J. Gong. 2004. Dendritic cells fused with human cancer cells: morphology, antigen expression and T cell stimulation. Clin. Immunol. 113: 261-269.
15. Gong, J., D. Avigan, D. Chen, Z. Wu, S. Koido, M. Kashiwaba, and D. Kufe. 2000. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA 97: 2715-2718.
16. Koido, S., E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, et al. 2005. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11: 7891-7900.
17. Trefzer, U., G. Weingart, Y. Chen, G. Herberth, K. Adrian, H. Winter, H. Audring, Y. Guo, W. Sterry, and P. Walden. 2000. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int. J. Cancer 85: 618-626.
18. Homma, S., K. Matai, M. Irie, T. Ohno, D. Kufe, and G. Toda. 2003. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol. 38: 989-994.
19. Kikuchi, T., Y. Akasaki, T. Abe, T. Fukuda, H. Saotome, J. L. Ryan, D. W. Kufe, and T. Ohno. 2004. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27: 452-459.
20. Avigan, D., B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atokins, J. Mier, D. McDermott, T. Smith, et al. 2004. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10:4699-4708.
21. Homma, S., T. Kikuchi, N. Ishiji, K. Ochiai, H. Takeyama, H. Saotome, Y. Sagawa, E. Hara, D. Kufe, J. L. Ryan, et al. 2005. Cancer Immunotherapy by fusion of dendritic and tumor cells and rh-IL-12. Eur. J. Clin. Invest. 35: 279-286.
22. Homma, S., Y. Sagawa, T. Ito, T. Ohno, and G. Toda. 2006. Cancer immunotherapy using dendritic/tumor-fusion vaccine induces elevation of serum antinuclear antibody with better clinical responses. Clin. Exp. Immunol. 144: 41-47.
23. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21: 685-711.
24. Roake, J. A., P. J. Rao, P. J. Morris, C. P. Larsen, D. F. Hankins, and J. M. Austyn. 1995. Dendritic cells loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J. Exp. Med. 181: 2237-2247.
25. Shitara, K., O. Ichimura, T. Mitsuno, and T. Osawa. 1985. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432. J. Immunol. 134: 1039-1047.
26. Fujimoto, T., R. B. Duda, A. Szilvasi, X. Chen, M. Mai, and M. A. O'Donnell. 1997. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell I dominant state. J. Immunol. 158: 5619-5626.
27. Kuroki, H., M. Morisaki, K. Matsumoto, H. Onishi, E. Baba, M. Tanaka, and M. Katano. 2003. Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol. Immunother. 52: 561-568.
28. Okamoto, M., S. Furuichi, Y. Nishioka, T. Oshikawa, T. Tano, S. U. Ahmed, K. Takeda, S. Akira, Y. Ryoma, Y. Moriya, et al. 2004. Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with active component of OK-432, a streptococcal preparation. Cancer Res. 64: 5461-5470.
29. Misaki, T., Y. Watanabe, Y. Iida, A. Hidaka, K. Kasagi, H. Fukushima, and J. Konishi. 1992. Recruitment of T lymphocytes and induction of tumor necrosisi factor in thyroid cancer by a local immunotherapy. Cancer Immunol. Immunother. 35: 92-96.
30. Nakahara, S., T. Tsunoda, T. Baba, S. Asabe, and H. Tahara. 2003. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63: 4112-4118.
31. Itoh, T., Y. Ueda, K. Okugawa, H. Fujiwara, N. Fuji, T. Yamashita, H. Fujiki, S. Harada, T. Yoshimura, and H. Yamagishi. 2003. Streptococcal preparation OK 432 promote functional maturation of human monocyte-derived dendritic cells. Cancer Immunol. Immunother. 52: 207-214.
32. Yamanaka, R., J. Homma, N. Yajima, N. Tsuchiya, M. Sano, T. Kobayashi, S. Yoshida, T. Abe, M. Narita, M. Takahashi, and R. Tanaka. 2005. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer Res. 11: 4160-4167.
33. Ono, T., M. Harada, A. Yamada, M. Tanaka, Y. Takao, Y. Tanaka, T. Mine, K. Sakamoto, T. Nakashima, and K. Itoh. 2006. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432. Clin. Cancer Res. 12: 1325-1332.
34. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
35. Liu, L., A. Chahroudi, G. Silvestri, M. E. Wernett, W. J. Kaiser, J. T. Safrit, A. Komoriya, J. D. Altman, B. Z. Packard, and M. B. Feinberg. 2002. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8: 185-189.
36. Jerome, K. R., D. D. Sloan, and M. Aubert. 2003. Measuring T cell-mediated cytotoxicity using antibody to activated caspase 3. Nat. Med. 9: 4-5.
37. Koido, S., N. Nikrui, M. Ohana, J. Xia, Y. Tanaka, C. Liu, J. Durfee, A. Lerner, and J. Gong. 2005. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol. Oncol. 99: 462-471.
38. Hasbold, J., A. V. Gett, J. S. Rush, E. Deenick, D. Avery, J. Jun, and P. D. Hodgkin. 1999. Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinymidyl ester. Immunol. Cell Biol. 77: 516-522.
39. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2: 415-422.
40. Schaft, N., J. Dorrie, P. Thumann, V. E. Beck, I. Muller, E. S. Schultz, E. Kampgen, D. Dieckmann, and G. Schuler. 2005. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 174: 3087-3097.
41. Bonehill, A., C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. van der Bruggen, and K. Thielemans. 2004. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. 2005. J. Immunol. 172: 6649-6657.
42. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A. L. Peitrequin, B. Monsarrat, R. Van Velthoven, J. C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12: 107-117.
43. Schultz, E. S., J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier, V. Russo, S. Morel, F. Levy, T. Boon, et al. 2002. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195: 391-399.
44. + cytotoxic T lymphocytes. J. Exp. Med. 187: 49-57.
45. + T cells in vivo. J. Immunol. 163: 2561-2567.
46. + CTL responses in vitro. J. Clin. Invest. 98: 715-722.
47. Gong, J., S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe. 2000. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99: 2512-2517.
48. + T cell effector function in situ. Blood 98: 2143-2151.
49. Cisco, R. M., Z. Abdel-Wahab, J. Dannull, S. Nair, D. S. Tyler, E. Gilboa, J. Vieweg, Y. Daaka, and S. K. Pruitt. 2004. Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive Toll-like receptor 4. 2004. J. Immunol. 172: 7162-7168.
50. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune responses by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33.